DGX has done better than both the industry and the S&P 500 over the last year, thanks to its solid core performance and the benefits from its acquisitions.
DGX remains a focus for investors because of its strong potential in Advanced Diagnostics and its advancements in acquiring new companies.
SECAUCUS, N.J., Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a top provider of diagnostic information services, is set to hold an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025, at the New York Stock Exchange.
Is Quest Diagnostics (DGX) a strong choice for momentum investors? Let's take a closer look.
On Thursday, Quest Diagnostics (NYSE: DGX) stock was close to reaching its highest value ever, which is impressive for a company that has been listed for many years. By late afternoon, the healthcare testing company's shares had risen over 5%, significantly outperforming the S&P 500 index, which was up by 0.8%. During this period, Quest reported a revenue of $2.62 billion, showing a strong year-over-year growth of almost 15%.
SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a top provider of diagnostic information services, has been recognized by Fortune® magazine as one of the 2025 World's Most Admired Companies™. This marks the 11th year in a row that the company has made it onto this prestigious list of respected global businesses.
On Thursday, Quest Diagnostics (DGX 5.49%) stock was close to reaching its highest price ever, which is impressive for a company that has been listed for many years. By late afternoon, the healthcare testing company's shares had risen over 5%, significantly outperforming the S&P 500 index, which was up by 0.8% at the same time.
Quest Diagnostics Incorporated (NYSE:DGX) will hold its Q4 2024 Earnings Conference Call on January 30, 2025, at 8:30 AM ET. The call will feature company leaders, including President & CEO Jim Davis and EVP & CFO Sam Samad. Various analysts from different firms will also participate in the discussion.
Quest Diagnostics (DGX 6.36%), a top company in diagnostic testing and information services, announced its fourth quarter results on January 30. The company had a strong quarter, with adjusted earnings per share (EPS) of $2.23, which was higher than the analysts' estimate of $2.18.
Quest Diagnostics (DGX) reported quarterly earnings of $2.23 per share, which is higher than the Zacks Consensus Estimate of $2.19 per share. This is an increase compared to earnings of $2.15 per share from the same period last year.